Changes of 18 F-fluoro-2-deoxyglucose position-emission tomography findings by the eradication of Helicobacter pylori in the stomach

Helicobacter. 2021 Jun;26(3):e12797. doi: 10.1111/hel.12797. Epub 2021 Mar 8.

Abstract

Purpose: Helicobacter pylori (HP) infection is reported to increase 18 F-fluoro-2-deoxyglucose (FDG) accumulation in the stomach. The accumulation of FDG by positron-emission tomography (FDG-PET) in the stomach for the voluntary health examinees of cancer checkup was examined before and after the HP eradication.

Subjects and methods: From March 2013 to October 2015, eighty-one subjects were performed FDG-PET to detect cancer at the health checkup. All of them were also surveyed by esophagogastroduodenoscopy. Subjects were classified as the 33 cases of HP positive (group A), 38 cases of originally negative (group B), and the 10 negative cases by HP eradication therapy (group C). Group A was treated by combination of amoxicillin, clarithromycin, and proton pump inhibitor for a week, and all of them eradicated HP. A part of group A (n = 7) was serially performed FDG-PET one to five years after the treatment and compared the maximum standard uptake value of FDG (SUV) around the fundic gland region.

Results: SUV of group A (3.55 ± 0.69) was significantly higher than those of both group B (2.96 ± 0.72) and group C (2.89 ± 0.51) (p < 0.01, respectively). Groups B and C are almost comparable and showed no significant difference during the course. In group A, HP eradication significantly decreased the SUV to 3.1 ± 0.43 (P < .01). SUV after the eradication was significantly reduced (P < .01) in the mild to moderate atrophy (C1-C3) group according to Kimura and Takemoto classification of chronic gastritis of group A. Although SUV in the advanced atrophy group (O1-O3) tended to decline after the eradication, the change was not significant.

Conclusion: HP-infected stomach showed higher FDG uptake in the fundic gland region and HP eradication decreased the uptake in the mild to moderate atrophic gastritis but not in the severe atrophic gastritis.

Keywords: FDG-PET; atrophic gastritis; eradication therapy; helicobacter pylori.

MeSH terms

  • Amoxicillin / therapeutic use
  • Anti-Bacterial Agents / therapeutic use
  • Clarithromycin / therapeutic use
  • Deoxyglucose / therapeutic use
  • Drug Therapy, Combination
  • Fluorodeoxyglucose F18 / pharmacokinetics*
  • Gastric Mucosa / metabolism*
  • Gastritis / diagnosis*
  • Gastritis / microbiology
  • Helicobacter Infections* / drug therapy
  • Helicobacter pylori
  • Humans
  • Positron-Emission Tomography*
  • Stomach
  • Stomach Neoplasms
  • Tomography

Substances

  • Anti-Bacterial Agents
  • Fluorodeoxyglucose F18
  • Amoxicillin
  • Deoxyglucose
  • Clarithromycin